Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 5

Aripiprazole in the treatment of Huntington’s disease: a case series

Authors Andrea Ciammola, Jenny Sassone, Clarissa Colciago, Niccolò E Mencacci, Barbara Poletti, et al

Published Date November 2008 Volume 2009:5 Pages 1—4

DOI http://dx.doi.org/10.2147/NDT.S4165

Published 25 November 2008

Andrea Ciammola1, Jenny Sassone1, Clarissa Colciago1, Niccolò E Mencacci1, Barbara Poletti1, Andrea Ciarmiello2, Ferdinando Squitieri3, Vincenzo Silani1

1Department of Neurology and Laboratory of Neuroscience, “Dino Ferrari” Centre, University of Milan Medical School – IRCCS Istituto Auxologico Italiano, Milano, Italy; 2Unit of Nuclear Medicine, S. Andrea Hospital, La Spezia, Italy; 3Neurogenetics Unit, IRCCS Neuromed, Pozzilli (IS), Italy

Objectives: The aim of the study was to describe the effects of aripiprazole, a new atypical antipsychotic drug that acts as a partial dopamine agonist on motor, behavioral and cognitive functions in patients with genetically confirmed Huntington’s disease (HD).

Methods and results: Three HD patients were evaluated for Unified Huntington Disease Rating Scale part I and II and Beck Depression Inventory at baseline, after two months and one-year treatment. Aripiprazole effectively controlled involuntary movements and psychiatric symptoms, with effects on cognitive functions.

Conclusions: Our case reports suggest that aripiprazole is well tolerated, remarkably improving some of the motor and behavioral symptoms in patients affected by HD. Randomized, controlled, long-term studies are warranted.

Keywords: Huntington’s disease, aripiprazole, treatment, chorea

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Self-assembled micelles of amphiphilic poly(L-phenylalanine)-b-poly(L-serine) polypeptides for tumor-targeted delivery

Zhao ZM, Wang Y, Han J, Wang KL, Yang D, Yang YH, Du Q, Song YJ, Yin XX

International Journal of Nanomedicine 2014, 9:5849-5862

Published Date: 12 December 2014

Silica nanoparticles induce autophagy and endothelial dysfunction via the PI3K/Akt/mTOR signaling pathway

Duan J, Yu Y, Yu Y, Li Y, Wang J, Geng W, Jiang L, Li Q, Zhou X, Sun Z

International Journal of Nanomedicine 2014, 9:5131-5141

Published Date: 5 November 2014

A histological evaluation and in vivo assessment of intratumoral near infrared photothermal nanotherapy-induced tumor regression

Green HN, Crockett SD, Martyshkin DV, Singh KP, Grizzle WE, Rosenthal EL, Mirov SB

International Journal of Nanomedicine 2014, 9:5093-5102

Published Date: 5 November 2014

Determination of factors controlling the particle size and entrapment efficiency of noscapine in PEG/PLA nanoparticles using artificial neural networks

Shalaby KS, Soliman ME, Casettari L, Bonacucina G, Cespi M, Palmieri GF, Sammour OA, El Shamy AA

International Journal of Nanomedicine 2014, 9:4953-4964

Published Date: 23 October 2014

The Yamaguchi fox/pigeon-imitation test, a brief cognitive performance rating tool, in a community-dwelling population: normative data for Japanese subjects – a preliminary study

Ishioka M, Sugawara N, Kaneda A, Okubo N, Iwane K, Takahashi I, Yasui-Furukori N

Neuropsychiatric Disease and Treatment 2014, 10:1721-1725

Published Date: 11 September 2014

PLGA nanofiber membranes loaded with epigallocatechin-3-O-gallate are beneficial to prevention of postsurgical adhesions

Shin YC, Yang WJ, Lee JH, Oh JW, Kim TW, Park JC, Hyon SH, Han DW

International Journal of Nanomedicine 2014, 9:4067-4078

Published Date: 22 August 2014

Self-assembled or mixed peptide amphiphile micelles from Herpes simplex virus glycoproteins as potential immunomodulatory treatment

Accardo A, Vitiello M, Tesauro D, Galdiero M, Finamore E, Martora F, Mansi R, Ringhieri P, Morelli G

International Journal of Nanomedicine 2014, 9:2137-2148

Published Date: 7 May 2014

Current and future initiatives for vascular health management in clinical practice

Cameron JD, Asmar R, Struijker-Boudier H, Shirai K, Sirenko Y, Kotovskaya Y, Topouchian J

Vascular Health and Risk Management 2013, 9:255-264

Published Date: 28 May 2013

ESR rate can be a marker for coronary artery disease

Eghbal Eftekhaari T

Vascular Health and Risk Management 2012, 8:669-670

Published Date: 18 December 2012